NASDAQ:ISEE - IVERIC bio Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $16.00
  • Forecasted Upside: 78.77 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$8.95
▲ +0.05 (0.56%)

This chart shows the closing price for ISEE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New IVERIC bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ISEE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ISEE

Analyst Price Target is $16.00
▲ +78.77% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for IVERIC bio in the last 3 months. The average price target is $16.00, with a high forecast of $16.00 and a low forecast of $16.00. The average price target represents a 78.77% upside from the last price of $8.95.

This chart shows the closing price for ISEE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in IVERIC bio. This rating has held steady since July 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/1/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/1/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/30/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/28/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/26/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/26/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/25/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/6/2021Credit Suisse GroupBoost Price TargetPositive ➝ Outperform$14.00 ➝ $16.00High
8/13/2020Credit Suisse GroupInitiated CoverageOutperform$13.00High
5/25/2020WedbushReiterated RatingOutperform ➝ Market Perform$13.00Low
1/24/2020CowenInitiated CoverageOutperformLow
1/6/2020WedbushInitiated CoverageOutperformMedium
9/18/2019Chardan CapitalReiterated RatingHold$1.25Low
(Data available from 7/25/2016 forward)
IVERIC bio logo
IVERIC bio, Inc., a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company is developing Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It is also developing STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of leber congenital amaurosis type 10 (LCA10) and autosomal recessive stargardt disease (STGD1); IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases; IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and IC-200 for the treatment of IRDs associated with mutations in the BEST1 gene. In addition, the company develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of Zimura monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of Zimura administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. Its discovery and research programs include miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related IRDs. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. IVERIC bio, Inc. was incorporated in 2007 and is based in New York, New York.
Read More

Today's Range

Now: $8.95
Low: $8.51
High: $9.19

50 Day Range

MA: $7.38
Low: $5.86
High: $9.79

52 Week Range

Now: $8.95
Low: $3.97
High: $10.25

Volume

1,512,373 shs

Average Volume

3,552,462 shs

Market Capitalization

$808.99 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.67

Frequently Asked Questions

What sell-side analysts currently cover shares of IVERIC bio?

The following Wall Street analysts have issued research reports on IVERIC bio in the last twelve months: Credit Suisse Group AG, and Zacks Investment Research.
View the latest analyst ratings for ISEE.

What is the current price target for IVERIC bio?

1 Wall Street analysts have set twelve-month price targets for IVERIC bio in the last year. Their average twelve-month price target is $16.00, suggesting a possible upside of 78.8%. Credit Suisse Group AG has the highest price target set, predicting ISEE will reach $16.00 in the next twelve months. Credit Suisse Group AG has the lowest price target set, forecasting a price of $16.00 for IVERIC bio in the next year.
View the latest price targets for ISEE.

What is the current consensus analyst rating for IVERIC bio?

IVERIC bio currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ISEE will outperform the market and that investors should add to their positions of IVERIC bio.
View the latest ratings for ISEE.

What other companies compete with IVERIC bio?

How do I contact IVERIC bio's investor relations team?

IVERIC bio's physical mailing address is ONE PENN PLAZA 35TH FLOOR, NEW YORK NY, 10119. The company's listed phone number is 212-845-8200 and its investor relations email address is [email protected] The official website for IVERIC bio is ivericbio.com.